After demonstrating the key role of lncRNA-PI3K axis in regulating TKI resistance, we explored the therapeutic potential of PI3K inhibitor alpelisib in treating patients with resistant CML. Here, PIK3CG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.